Abstract:Abstract p53 is an attractive therapeutic target in oncology since aberrant regulation of p53 expression is associated with cancer development and progression. HDM2 is a primary negative regulator of p53 function in cells. The blockade of the p53-HDM2 interaction presents an attractive approach for development of drugs against tumors expressing wild-type p53. Here we report a novel and potent small molecule antagonist of HDM2, SCH 1450206. It binds selectively to the HDM2 protein with high affinity, with weak affinity to HDMX protein. SCH 1450206 induced dose- and time-dependent stabilization of p53 protein and its downstream targets in several human cancer cell lines with wild-type p53, but not in cell with p53 gene deletion. SCH 1450206-induced stabilization of p53 led to distinct changes in expression of p53 target genes regulating apoptosis and cell cycle checkpoints. Inhibition of cell proliferation and induction of apoptosis were surveyed in a panel of human tumor cell lines following SCH 1450206 treatment. Inactivation of p53 by shRNA in cell lines expressing wt-p53 abolished the inhibition of cell proliferation and appearance of senescence in response to SCH 1450206, suggesting the cellular activity of SCH 1450206 is p53 specific and mechanism-based. Taken together, our results demonstrated the mechanism of action of SCH 1450206, a novel HDM2 antagonist that can activate the p53 pathway, and offers a potential anti-tumor agent targeting tumors expressing wild-type p53. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4534.

Molecular characterization of the hdm2-p53 interaction

Identification of novel mdm2 binding peptides by phage display.

Inhibition of Nonsense-Mediated Decay Rescues Functional P53β/γ Isoforms in MDM2-amplified Cancers

Small Molecule Inhibitors of the P53-Mdm2

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

Small-molecule inhibitors of the p53 suppressor HDM2: have protein–protein interactions come of age as drug targets?

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

190 Novel Classes of P53 Activators for Cancer Therapy

Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2

Comparative study of the p53-mdm2 and p53-MDMX interfaces

Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells

The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo

D-Peptide Inhibitors of the P53-Mdm2 Interaction for Targeted Molecular Therapy of Malignant Neoplasms

MDM2: current research status and prospects of tumor treatment

The Facile and Visualizable Identification of Broad-Spectrum Inhibitors of MDM2/p53 Using Co-Expressed Protein Complexes

Case Study: discovery of inhibitors of the MDM2-p53 protein-protein interaction.

Abstract 4534: A Novel and Potent Small Molecule Antagonist of HDM2, SCH 1450206, Activates the P53 Pathway with Mechanism-Based Activity

Abstract 2785: Discovery of a Novel HDM2 Inhibitor with Potent in Vivo Anti-Tumor Activity